Similar insulin secretory response to a gastric inhibitory polypeptide bolus injection at euglycemia in first-degree relatives of patients with type 2 diabetes and control subjects

Creutzfeldt, 1979, The incretin concept today, Diabetologia, 16, 75, 10.1007/BF01225454 Creutzfeldt, 1992, Gut hormones and diabetes mellitus, Diabetes Metab Rev, 8, 149, 10.1002/dmr.5610080206 Jones, 1987, The effects of glucose-dependent insulinotropic polypeptide infused at physiological concentrations in normal subjects and type 2 (non-insulin-dependent) diabetic patients on glucose tolerance and B-cell secretion, Diabetologia, 30, 707, 10.1007/BF00296993 Amland, 1985, Effects of intravenously infused porcine GIP on serum insulin, plasma C-peptide, and pancreatic polypeptide in non-insulin-dependent diabetes in the fasting state, Scand J Gastroenterol, 20, 315, 10.3109/00365528509091657 Nauck, 1993, Preserved incretin activity of glucagon-like peptide 1 [7–36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus, J Clin Invest, 91, 301, 10.1172/JCI116186 Holst, 1997, The pathogenesis of NIDDM involves a defective expression of the GIP receptor, Diabetologia, 40, 984, 10.1007/s001250050779 Meier, 2002, Gastric inhibitory polypeptide (GIP), Regul Peptides, 107, 1, 10.1016/S0167-0115(02)00039-3 Meier, 2001, Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes, Diabetes, 50, 2497, 10.2337/diabetes.50.11.2497 Meier, 2002, Insulin secretion following a bolus injection of gastric inhibitory polypeptide (GIP) in first-degree relatives of type 2 diabetic patients and healthy control subjects, Diabetes, 51, A580 Deacon, 2000, Degradation of endogenous and exogenous gastric inhibitory polypeptide (GIP) in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide, J Clin Endocrinol Metab, 85, 3575, 10.1210/jc.85.10.3575 Matthews, 1985, Homeostasis model assessment, Diabetologia, 28, 412, 10.1007/BF00280883 Vilsbøll, 2001, Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients, Diabetes, 50, 609, 10.2337/diabetes.50.3.609 Vilsbøll, 2002, Defective amplification of the late phase insulin response to glucose by GIP in obese type II diabetic patients, Diabetologia, 45, 1111, 10.1007/s00125-002-0878-6 Pederson, 1978, Interaction of gastric inhibitory polypeptide, glucose, and arginine on insulin and glucagon secreton from the perfused rat pancreas, Endocrinol, 103, 610, 10.1210/endo-103-2-610 Dupré, 1973, Stimulation of insulin secretion by gastric inhibitory polypeptide in man, J Clin Endocrinol Metab, 37, 826, 10.1210/jcem-37-5-826 Nauck, 1993, Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7–36) amide infused at near-physiological insulinotropic hormone and glucose concentrations, J Clin Endocrinol Metab, 76, 912, 10.1210/jc.76.4.912 Pratley, 2001, The role of impaired early insulin secretion in the pathogenesis of type II diabetes mellitus, Diabetologia, 44, 929, 10.1007/s001250100580 Halter, 1979, Potentiation of insulin secretory responses by plasma glucose levels in man, J Clin Endocrinol Metab, 48, 946, 10.1210/jcem-48-6-946 Pfeifer, 1980, Potentiation of insulin secretion to nonglucose stimuli in normal man by tolbutamide, Diabetes, 29, 335, 10.2337/diabetes.29.5.335 Ward, 1984, Diminished B cell secretory capacity in patients with non-insulin-dependent diabetes mellitus, J Clin Invest, 74, 1318, 10.1172/JCI111542 Jorde, 1987, The insulinotropic effect of gastric inhibitory polypeptide in non-insulin dependent diabetes, Ital J Gastroenterol, 19, 76 Kubota, 1996, Identification of two missense mutations in the GIP receptor gene: A functional study and association analysis with NIDDM: No evidence of association with Japanese NIDDM subjects, Diabetes, 45, 1701, 10.2337/diabetes.45.12.1701 Amlind, 1998, Discovery of amino acid variants in the human glucose-dependent insulinotropic polypeptide (GIP) receptor, Diabetologia, 41, 1194, 10.1007/s001250051051 Lynn, 2001, Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker rats, Diabetes, 50, 1004, 10.2337/diabetes.50.5.1004 Nauck, 2001, Quantification of the incretin effect in first-degree relatives of type 2 diabetic patients compared to healthy control subjects, Diabetologia, 44, A195